ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXPLORES THE ASPIRATIONAL AND PRACTICAL ELEMENTS OF GENERATING REAL-WORLD EVIDENCE

Published Nov 2, 2016
Vienna, Austria—1 November 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) hosted an issue panel this afternoon entitled, Real World Evidence to Support Value Proposition and Reimbursement at Launch: The Aspirational Meets the Impractical?, at the Society’s 19th Annual European Congress in Vienna, Austria. The issue panel was moderated by Kari Edwards, PhD, Managing Partner, Harbinger Health, LLC, Los Angeles, CA, USA. Panelists for the session included:
  • Adrian R. Levy, PhD, Professor and Head, Community Health and Epidemiology, Dalhousie University, Nova Scotia, AL, Canada
  • Arie Barlev, PharmD, MS, Senior Director, Health Economics and Outcomes Research, Medivation, Inc., San Francisco, CA, USA
  • Andrew Briggs, DPhil, William R. Lindsay Chair of Health Economics and Professor of Health Economics, University of Glasgow, Glasgow, UK
The panelists explored the tension that exists between the aspirational and practical elements of generating real-world evidence in a timely fashion to support reimbursement for the launch of a new product launch. Kari Edwards, PhD presented a number of illustrative case studies to provide context and moderated the debate. Adrian R. Levy, PhD provided a payer perspective, arguing in favor of real-world evidence and noting that timely assessment of likely effectiveness would support reimbursement submissions upon product launch. Arie Barlev, PharmD, MS presented an industry view noting the practical challenges associated with collecting evidence within a short, post-approval timeframe, and highlighted the problem of selection bias when measuring relative effect in populations exposed to newly approved agents compared with standards of care. The final speaker, Andrew Briggs, DPhil, represented the health economics point of view and demonstrated the use of modeling techniques to exploit the rigorous nature of clinical trial data. Additional information on the ISPOR 19th Annual European Congress can be found here. Released presentations from the congress can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORVienna.

###

Related Stories

ISPOR Chief Science Officer Dr Laura Pizzi Named to NJBIZ's 2026 People to Watch in Healthcare List

Jul 29, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR) is proud to announce its Chief Science Officer, Laura Pizzi, PharmD, MPH, has been recognized by NJBIZ as one of its 2026 People to Watch in Healthcare.

ISPOR Publishes White Paper Focused on Systemic Coherence for Healthcare Decision Making in Europe

Jul 21, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced that it has released a new white paper, “Achieving Systemic Coherence for Healthcare Decision Making in Europe.”

ISPOR Announces the Healthcare Investment Summit 2026

Jul 20, 2026

ISPOR announced their inaugural Healthcare Investment Summit 2026, which will bring together healthcare investors, founders, pharma and device executives, policy experts, health economists, and access leaders on September 22–23, 2026, in San Francisco to examine the critical factors shaping investment decisions across the healthcare landscape.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×